Paradoxical effect of polymyxin B: High drug exposure amplifies resistance in Acinetobacter baumannii

Antimicrobial Agents and Chemotherapy

Volumn 60, Issue 7, 2016, Pages 3913-3920

  Tsuji, Brian T ^a   Landersdorfer, Cornelia B ^a,b   Lenhard, Justin R ^a   Cheah, Soon Ee ^b   Thamlikitkul, Visanu ^c   Rao, Gauri G ^a   Holden, Patricia N ^a   Forrest, Alan ^a,d   Bulitta, Jürgen B ^a,e   Nation, Roger L ^b   Li, Jian ^b  

^a UNIVERSITY AT BUFFALO   (United States)

^b MONASH UNIVERSITY   (Australia)

^c MAHIDOL UNIVERSITY   (Thailand)

^d UNIVERSITY OF NORTH CAROLINA   (United States)

^e UNIVERSITY OF FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLISTIMETHATE; POLYMYXIN B; ANTIINFECTIVE AGENT;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTION; ADULT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BACTERIAL COUNT; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATE; CLINICAL ARTICLE; COLONY FORMING UNIT; CONTROLLED STUDY; COST BENEFIT ANALYSIS; CRITICALLY ILL PATIENT; DOSE RESPONSE; DRUG DOSE INTENSIFICATION; DRUG DOSE REGIMEN; DRUG EXPOSURE; EC50; HUMAN; LIMIT OF QUANTITATION; NONHUMAN; PARADOXICAL DRUG REACTION; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; DRUG EFFECTS; ENTEROBACTERIACEAE; ENTEROCOCCUS FAECIUM; KLEBSIELLA PNEUMONIAE; MICROBIAL SENSITIVITY TEST; MULTIDRUG RESISTANCE; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS AUREUS;

ACINETOBACTER BAUMANNII; ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ENTEROBACTERIACEAE; ENTEROCOCCUS FAECIUM; KLEBSIELLA PNEUMONIAE; MICROBIAL SENSITIVITY TESTS; POLYMYXIN B; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS AUREUS;

EID: 84976863809     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02831-15     Document Type: Article

References (39)

1. Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D, Rice LB, Scheld M, Spellberg B, Bartlett J. 2009. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 48:1-12. http://dx.doi.org/10.1086/595011.
2. Lim LM, Ly N, Anderson D, Yang JC, Macander L, Jarkowski A, III, Forrest A, Bulitta JB, Tsuji BT. 2010. Resurgence of colistin: a review of resistance, toxicity, pharmacodynamics, and dosing. Pharmacotherapy 30:1279-1291. http://dx.doi.org/10.1592/phco.30.12.1279.
3. Nation RL, Li J, Cars O, Couet W, Dudley MN, Kaye KS, Mouton JW, Paterson DL, Tam VH, Theuretzbacher U, Tsuji BT, Turnidge JD. 2015. Framework for optimisation of the clinical use of colistin and polymyxin B: the Prato polymyxin consensus. Lancet Infect Dis 15:225-234. http://dx.doi.org/10.1016/S1473-3099(14)70850-3.
4. Walsh TR, Weeks J, Livermore DM, Toleman MA. 2011. Dissemination of NDM-1 positive bacteria in the New Delhi environment and its implications for human health: an environmental point prevalence study. Lancet Infect Dis 11:355-362. http://dx.doi.org/10.1016/S1473-3099(11)70059-7.
5. Arroyo LA, Mateos I, Gonzalez V, Aznar J. 2009. In vitro activities of tigecycline, minocycline, and colistin-tigecycline combination against multi- and pandrug-resistant clinical isolates of Acinetobacter baumannii group. Antimicrob Agents Chemother 53:1295-1296. http://dx.doi.org/10.1128/AAC.01097-08.
6. Liu YY, Wang Y, Walsh TR, Yi LX, Zhang R, Spencer J, Doi Y, Tian G, Dong B, Huang X, Yu LF, Gu D, Ren H, Chen X, Lv L, He D, Zhou H, Liang Z, Liu JH, Shen J. 2016. Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological study. Lancet Infect Dis 16:161-168. http://dx.doi.org/10.1016/S1473-3099(15)00424-7.
7. Sandri AM, Landersdorfer CB, Jacob J, Boniatti MM, Dalarosa MG, Falci DR, Behle TF, Bordinhao RC, Wang J, Forrest A, Nation RL, Li J, Zavascki AP. 2013. Population pharmacokinetics of intravenous polymyxin B in critically ill patients: implications for selection of dosage regimens. Clin Infect Dis 57:524-531. http://dx.doi.org/10.1093/cid/cit334.
8. Sandri AM, Landersdorfer CB, Jacob J, Boniatti MM, Dalarosa MG, Falci DR, Behle TF, Saitovitch D, Wang J, Forrest A, Nation RL, Zavascki AP, Li J. 2013. Pharmacokinetics of polymyxin B in patients on continuous venovenous haemodialysis. J Antimicrob Chemother 68:674-677. http://dx.doi.org/10.1093/jac/dks437.
9. Garonzik SM, Li J, Thamlikitkul V, Paterson DL, Shoham S, Jacob J, Silveira FP, Forrest A, Nation RL. 2011. Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrob Agents Chemother 55:3284-3294. http://dx.doi.org/10.1128/AAC.01733-10.
10. Kwa AL, Abdelraouf K, Low JG, Tam VH. 2011. Pharmacokinetics of polymyxin B in a patient with renal insufficiency: a case report. Clin Infect Dis 52:1280-1281. http://dx.doi.org/10.1093/cid/cir137.
11. Li J, Rayner CR, Nation RL, Owen RJ, Spelman D, Tan KE, Liolios L. 2006. Heteroresistance to colistin in multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother 50:2946-2950. http://dx.doi.org/10.1128/AAC.00103-06.
12. Cai Y, Chai D, Wang R, Liang B, Bai N. 2012. Colistin resistance of Acinetobacter baumannii: clinical reports, mechanisms and antimicrobial strategies. J Antimicrob Chemother 67:1607-1615. http://dx.doi.org/10.1093/jac/dks084.
13. Qureshi ZA, Hittle LE, O'Hara JA, Rivera JI, Syed A, Shields RK, Pasculle AW, Ernst RK, Doi Y. 2015. Colistin-resistant Acinetobacter baumannii: beyond carbapenem resistance. Clin Infect Dis 60:1295-1303. http://dx.doi.org/10.1093/cid/civ048.
14. Barin J, Martins AF, Heineck BL, Barth AL, Zavascki AP. 2013. Heteroand adaptive resistance to polymyxin B in OXA-23-producing carbapenem-resistant Acinetobacter baumannii isolates. Ann Clin Microbiol Antimicrob 12:15. http://dx.doi.org/10.1186/1476-0711-12-15.
15. Rao GG, Ly NS, Haas CE, Garonzik S, Forrest A, Bulitta JB, Kelchlin PA, Holden PN, Nation RL, Li J, Tsuji BT. 2014. New dosing strategies for an old antibiotic: pharmacodynamics of front-loaded regimens of colistin at simulated pharmacokinetics in patients with kidney or liver disease. Antimicrob Agents Chemother 58:1381-1388. http://dx.doi.org/10.1128/AAC.00327-13.
16. Bulitta JB, Yang JC, Yohonn L, Ly NS, Brown SV, D'Hondt RE, Jusko WJ, Forrest A, Tsuji BT. 2010. Attenuation of colistin bactericidal activity by high inoculum of Pseudomonas aeruginosa characterized by a new mechanism-based population pharmacodynamic model. Antimicrob Agents Chemother 54:2051-2062. http://dx.doi.org/10.1128/AAC.00881-09.
17. Zaccard CR, Schell RF, Spiegel CA. 2009. Efficacy of bilateral bronchoalveolar lavage for diagnosis of ventilator-associated pneumonia. J Clin Microbiol 47:2918-2924. http://dx.doi.org/10.1128/JCM.00747-09.
18. American Thoracic Society, Infectious Diseases Society of America. 2005. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 171:388-416. http://dx.doi.org/10.1164/rccm.200405-644ST.
19. Ly NS, Bulitta JB, Rao GG, Landersdorfer CB, Holden PN, Forrest A, Bergen PJ, Nation RL, Li J, Tsuji BT. 2015. Colistin and doripenem combinations against Pseudomonas aeruginosa: profiling the time course of synergistic killing and prevention of resistance. J Antimicrob Chemother 70:1434-1442. http://dx.doi.org/10.1093/jac/dku567.
20. Drusano GL, Bonomo RA, Bahniuk N, Bulitta JB, Vanscoy B, Defiglio H, Fikes S, Brown D, Drawz SM, Kulawy R, Louie A. 2012. Resistance emergence mechanism and mechanism of resistance suppression by tobramycin for cefepime for Pseudomonas aeruginosa. Antimicrob Agents Chemother 56:231-242. http://dx.doi.org/10.1128/AAC.05252-11.
21. Cheah SE, Bulitta JB, Li J, Nation RL. 2014. Development and validation of a liquid chromatography-mass spectrometry assay for polymyxin B in bacterial growth media. J Pharm Biomed Anal 92:177-182. http://dx.doi.org/10.1016/j.jpba.2014.01.015.
22. Tsuji BT, von Eiff C, Kelchlin PA, Forrest A, Smith PF. 2008. Attenuated vancomycin bactericidal activity against Staphylococcus aureus hemB mutants expressing the small-colony-variant phenotype. Antimicrob Agents Chemother 52:1533-1537. http://dx.doi.org/10.1128/AAC.01254-07.
23. Peleg AY, Seifert H, Paterson DL. 2008. Acinetobacter baumannii: emergence of a successful pathogen. Clin Microbiol Rev 21:538-582. http://dx.doi.org/10.1128/CMR.00058-07.
24. Lee HJ, Bergen PJ, Bulitta JB, Tsuji B, Forrest A, Nation RL, Li J. 2013. Synergistic activity of colistin and rifampin combination against multidrug-resistant Acinetobacter baumannii in an in vitro pharmacokinetic/pharmacodynamic model. Antimicrob Agents Chemother 57:3738-3745. http://dx.doi.org/10.1128/AAC.00703-13.
25. Tam VH, Schilling AN, Vo G, Kabbara S, Kwa AL, Wiederhold NP, Lewis RE. 2005. Pharmacodynamics of polymyxin B against Pseudomonas aeruginosa. Antimicrob Agents Chemother 49:3624-3630. http://dx.doi.org/10.1128/AAC.49.9.3624-3630.2005.
26. Dudhani RV, Turnidge JD, Nation RL, Li J. 2010. fAUC/MIC is the most predictive pharmacokinetic/pharmacodynamic index of colistin against Acinetobacter baumannii in murine thigh and lung infection models. J Antimicrob Chemother 65:1984-1990. http://dx.doi.org/10.1093/jac/dkq226.
27. Tam VH, Louie A, Deziel MR, Liu W, Drusano GL. 2007. The relationship between quinolone exposures and resistance amplification is characterized by an inverted U: a new paradigm for optimizing pharmacodynamics to counterselect resistance. Antimicrob Agents Chemother 51:744-747. http://dx.doi.org/10.1128/AAC.00334-06.
28. Vanscoy B, Mendes RE, Castanheira M, McCauley J, Bhavnani SM, Forrest A, Jones RN, Okusanya OO, Friedrich LV, Steenbergen J, Ambrose PG. 2013. Relationship between ceftolozane-tazobactam exposure and drug resistance amplification in a hollow-fiber infection model. Antimicrob Agents Chemother 57:4134-4138. http://dx.doi.org/10.1128/AAC.00461-13.
29. Drusano GL, Liu W, Fikes S, Cirz R, Robbins N, Kurhanewicz S, Rodriquez J, Brown D, Baluya D, Louie A. 2014. Interaction of drug- and granulocyte-mediated killing of Pseudomonas aeruginosa in a murine pneumonia model. J Infect Dis 210:1319-1324. http://dx.doi.org/10.1093/infdis/jiu237.
30. Breslow JM, Meissler JJ, Jr, Hartzell RR, Spence PB, Truant A, Gaughan J, Eisenstein TK. 2011. Innate immune responses to systemic Acinetobacter baumannii infection in mice: neutrophils, but not interleukin-17, mediate host resistance. Infect Immun 79:3317-3327. http://dx.doi.org/10.1128/IAI.00069-11.
31. de Breij A, Eveillard M, Dijkshoorn L, van den Broek PJ, Nibbering PH, Joly-Guillou ML. 2012. Differences in Acinetobacter baumannii strains and host innate immune response determine morbidity and mortality in experimental pneumonia. PLoS One 7:e30673. http://dx.doi.org/10.1371/journal.pone.0030673.
32. Mortensen BL, Skaar EP. 2012. Host-microbe interactions that shape the pathogenesis of Acinetobacter baumannii infection. Cell Microbiol 14:1336-1344. http://dx.doi.org/10.1111/j.1462-5822.2012.01817.x.
33. Beceiro A, Moreno A, Fernandez N, Vallejo JA, Aranda J, Adler B, Harper M, Boyce JD, Bou G. 2014. Biological cost of different mechanisms of colistin resistance and their impact on virulence in Acinetobacter baumannii. Antimicrob Agents Chemother 58:518-526. http://dx.doi.org/10.1128/AAC.01597-13.
34. Henry R, Crane B, Powell D, Deveson Lucas D, Li Z, Aranda J, Harrison P, Nation RL, Adler B, Harper M, Boyce JD, Li J. 2015. The transcriptomic response of Acinetobacter baumannii to colistin and doripenem alone and in combination in an in vitro pharmacokinetics/pharmacodynamics model. J Antimicrob Chemother 70:1303-1313. http://dx.doi.org/10.1093/jac/dku536.
35. Henry R, Vithanage N, Harrison P, Seemann T, Coutts S, Moffatt JH, Nation RL, Li J, Harper M, Adler B, Boyce JD. 2012. Colistin-resistant, lipopolysaccharide-deficient Acinetobacter baumannii responds to lipopolysaccharide loss through increased expression of genes involved in the synthesis and transport of lipoproteins, phospholipids, and poly-beta-1,6-N-acetylglucosamine. Antimicrob Agents Chemother 56:59-69. http://dx.doi.org/10.1128/AAC.05191-11.
36. Moffatt JH, Harper M, Harrison P, Hale JD, Vinogradov E, Seemann T, Henry R, Crane B, St Michael F, Cox AD, Adler B, Nation RL, Li J, Boyce JD. 2010. Colistin resistance in Acinetobacter baumannii is mediated by complete loss of lipopolysaccharide production. Antimicrob Agents Chemother 54:4971-4977. http://dx.doi.org/10.1128/AAC.00834-10.
37. Pogue JM, Lee J, Marchaim D, Yee V, Zhao JJ, Chopra T, Lephart P, Kaye KS. 2011. Incidence of and risk factors for colistin-associated nephrotoxicity in a large academic health system. Clin Infect Dis 53:879-884. http://dx.doi.org/10.1093/cid/cir611.
38. Abdelraouf K, Braggs KH, Yin T, Truong LD, Hu M, Tam VH. 2012. Characterization of polymyxin B-induced nephrotoxicity: implications for dosing regimen design. Antimicrob Agents Chemother 56:4625-4629. http://dx.doi.org/10.1128/AAC.00280-12.
39. Falagas ME, Kasiakou SK, Kofteridis DP, Roditakis G, Samonis G. 2006. Effectiveness and nephrotoxicity of intravenous colistin for treatment of patients with infections due to polymyxin-only-susceptible (POS) gram-negative bacteria. Eur J Clin Microbiol Infect Dis 25:596-599. http://dx.doi.org/10.1007/s10096-006-0191-2.